The need for better anti-complement drugs in certain complement mediated diseases and disease states remains pressing (1). The recent data published by Ueda et al. (2), appears to offer another highly effective solution to target complement activation in atypical haemolytic uraemic syndrome (aHUS).
No takes yet. Share an insight, caveat, or question.
Smith‐Jackson et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: